The effect of l-carnitine supplementation on serum leptin concentrations: a systematic review and meta-analysis of randomized controlled trials

Nazary-Vanani, Ali; Ghaedi, Ehsan; Mousavi, Seyed Mohammad; Teymouri, Alireza; Rahmani, Jamal; Varkaneh, Hamed Kord

doi:10.1007/s12020-018-1559-7

Cited by 13 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The serum level of leptin is proportional to the body fat mass. Thus, the level of leptin drops by decrease of the adipose tissue mass [29]. Moreover, obesity is a chronic in ammatory disease that causes lipid peroxidation by abnormal production of pro-in ammatory factors such as IL-6 and CRP as well as release of free fatty acids from adipose tissue [4].…”

Section: Discussionmentioning

confidence: 99%

“…Animal study also demonstrated that L-carnitine can reduce KOA symptoms [12]. Earlier studies showed that L-carnitine can signi cantly reduce CRP and MDA in coronary [29,30] and hemodialysis patients [31]. Meta-analysis also showed that L-carnitine supplementation signi cantly reduced the levels of CRP [13], cholesterol and lowdensity lipoprotein cholesterol (LDL-C) in diabetic patients [14].…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

L-Carnitine Supplementation could improve Clinical Symptom but not effect on C- reactive Protein and Malondialdehyde in Obese Women with Knee Osteoarthritis: A Double Blind Randomized Controlled Trial

Baghban

Hosseinzadeh

Mozaffari‐Khosravi

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgrounds:L-carnitine decreases oxidation and inflammation by reducing the fatty acid in plasma and using oxygen in ATP synthesis. So, knee osteoarthritis (KOA) can be improved by reducing apoptotic chondrocytes. The aim of this study was to compare the effect of L-carnitine supplementation along with low calorie diet and low calorie diet alone on improvement of KOA among obese women. In other words, we aimed to investigate the additional effect of L- carnitine on improvement of KOA among obese women who received low calorie diet.Methods76 obese women with KOA were randomly assigned into two low-calorie diet groups; the first one received the 1000 mg L-carnitine (LCG) and with the second group took the placebo (PLG) (n = 38). Anthropometry indices, body composition, lipid profile, C- reactive Protein (CRP), Malondialdehyde (MDA), and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) WOMAC index were assessed at the baseline and after 12 weeks. Results: At the end of the study, the LCG showed significant improvements compared with the PLG in the total WOMAC scores (17.41 ± 9.81 compared with 23.50 ± 12.02 (P = 0.024)); physical function (11.15 ± 6. 56 compared with 15.61 ± 8.17 (P = 0.014)); BMI (-1.21 ± 0.84 kg/m2 compared with − 0.79 ± 0.70 kg/m2 (P = 0.027)). However, MDA, total cholesterol, fat and visceral fat mass decreased only in LCG significantly, but not in the PLG. Other variables did not have any significant changes. Conclusion: Oral administration of 1000 mg L-carnitine in 12 weeks could improve WOMAC score and BMI, but not affect CRP, MDA, and lipid profile. Further trials with higher doses and longer durations, are required to verify our results. IRCT registration number: IRCT2017011932026N2. Registration date: 2017-04-27.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

L-Carnitine Supplementation could improve Clinical Symptom but not effect on C- reactive Protein and Malondialdehyde in Obese Women with Knee Osteoarthritis: A Double Blind Randomized Controlled Trial

Baghban

Hosseinzadeh

Mozaffari‐Khosravi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Karnitin kaynaklarının tükendiği hemodiyaliz hastalarında takviye olarak kullanımı yaygındır. L-Karnitinin çeşitli mekanizmalarla vücut ağırlığını azalttığı ve hipotalamusa doğrudan etki ederek iştahı ve besin alımını baskıladığı bildirilmektedir (Nazary-Vannani, 2018). Yapılan bir meta-analize göre Lkarnitin desteğinin, vücut yağ oranına etki etmese de vücut ağırlığı, BKİ, yağ kütlesi ve bel çevresini önemli ölçüde azalttığı sonucuna varmıştır (Askarpour, 2020).…”

Section: Gurmarunclassified

Besin Destekleri ve İlaçların Ağırlık Regülasyonuna Etkisi

YÜCEL

ÇİNTESUN

2022

İstanbul Sabahattin Zaim Üniversitesi Fen Bilimleri Enstitüsü Dergisi

View full text Add to dashboard Cite

Obez ve fazla vücut ağırlığına sahip olma durumu, dünyada yaklaşık olarak her üç kişiden birinde var olan metabolik bozukluklardan biri haline gelmiştir. Obezite tedavisi için en etkili çözüm, dengeli bir beslenme planı ile birlikte yaşam tarzı değişikliğinin oluşturulmasıdır. Ancak uzun vadede sürdürülmesi gereken bu yaşam tarzı değişikliği, obez bireylerin çoğu için uyum zorluğu nedeniyle başarısız sonuçlanmaktadır. Ağırlık kaybını sağlamadaki zorluklar bu kişileri, popülerliği artan besin desteklerine yöneltmektedir. Birçok bitkiden elde edilen ürünler, dünya nüfusunun çoğunluğu tarafından sağlığın iyileştirilmesi ve geliştirilmesi için kullanılmaktadır. Buna paralel olarak, obez ve fazla vücut ağırlığına sahip kişiler tarafından ağırlık kaybını destekleyeceği düşünülerek, besin desteklerinin kullanımı artış göstermiştir. Tüketilen besin desteklerinin içeriğindeki biyoaktif bileşikler; sindirim sisteminde görev alan enzimleri inhibe etme, lipit metabolizmasını arttırma, iştahı baskılama gibi çeşitli metabolik yollarla ağırlık regülasyonuna etki edebildiği varsayılarak fazla vücut ağırlığına sahip bireyler tarafından kullanılmaktadır. Bazı besin bileşenlerinin farklı metabolik yolaklarla ağırlık kontrolünü sağladığı bildirilmekle beraber, bunun aksi yönde insan sağlığını tehdit eden yan etkilerinin de olabileceği unutulmamalıdır. Bu nedenle, mevcut bilimsel veriler ve güvenli kullanım tavsiyelerinin dikkatlice araştırılması önem arz etmektedir. Bu derlemede, bazı besin desteklerinin ve ilaçların obeziteyi önlemedeki etki mekanizması araştırılmış, obeziteyi önleme ve tedavi etme stratejilerine bakış açısı sunmak amaçlanmıştır.

show abstract

“…Carnitine regulates lipid profiles by stimulating lipolysis and βoxidation, 5 as a result, lowering triglyceride, total cholesterol, and low-density lipoprotein cholestenone, 6 whereas has little effect on the Apo B100, Apo A1, and leptin. 7,8 Therefore, via the capability of converting fatty acid and antioxidative stress, carnitine has been used as pharmacological aid in many diseases including obesity, diabetes mellitus, and depression. [9][10][11][12][13][14] Currently, carnitine has also been used to improve insulin resistance (IR) and lipid metabolic disorders in women with PCOS, aiming to provide benefits for infertility.…”

Section: Introductionmentioning

confidence: 99%

Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis

Gong

Jiang

Hui

et al. 2023

Clinical Endocrinology

View full text Add to dashboard Cite

Objectives To quantify the effect of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with Polycystic ovary syndrome (PCOS). Design A systematic review and meta‐analysis were conducted. Patients Women with PCOS diagnosed by Rotterdam or Androgen Excess Society (AES) criteria and taking carnitine supplement were assessment. Measurements Fertility outcomes (ovulation, clinical pregnancy, live birth, and miscarriage), lipid parameters (BMI, triglyceride, total cholesterol, high‐density lipoprotein, low‐density lipoprotein), fasting glucose and insulin, and Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR). Results In total, 839 participants were included in this analysis. The dosage of carnitine and treatment duration reported by studies varied from 250 mg to 3000 mg daily and 84 to 90 days, respectively. The publication bias was absent. Compared with placebo, carnitine significantly improved ovulation rates (RR 3.42, 95% CI 2.39 to 4.89, I2 = 0%) and pregnancy rates (RR 11.05, 95% CI 1.21 to 100.58, I2 = 79%). None of included studies reported live birth. After treatment, carnitine resulted in significant reductions relative to baseline in body mass index (BMI, MD −0.93 kg/m2, 95% CI −1.15 to −0.70, I2 = 55.0%), insulin levels (MD −2.47 mIU/L, 95% CI −4.49 to −0.45, I2 = 0%) and the Homeostasis Model Assessment index (MD −0.67, 95% CI −1.20 to −0.14, I2 = 0%) than placebo, but not for lipid profiles including triglyceride, total cholesterol, and low‐density lipoprotein. Conclusion With the available literature, carnitine seems to improve ovulation and clinical pregnancy and insulin resistance, BMI in women with PCOS. These effects are warranted to be further validated, due to insufficient statistical power.

show abstract

The effect of l-carnitine supplementation on serum leptin concentrations: a systematic review and meta-analysis of randomized controlled trials

Abstract: L-carnitine consumption does not reduce serum leptin significantly. However, a significant effect on leptin was observed in diabetic patients and patients who received doses more than 3 mg per day in the course of <12 weeks.

Cited by 13 publications

References 48 publications

L-Carnitine Supplementation could improve Clinical Symptom but not effect on C- reactive Protein and Malondialdehyde in Obese Women with Knee Osteoarthritis: A Double Blind Randomized Controlled Trial

L-Carnitine Supplementation could improve Clinical Symptom but not effect on C- reactive Protein and Malondialdehyde in Obese Women with Knee Osteoarthritis: A Double Blind Randomized Controlled Trial

Besin Destekleri ve İlaçların Ağırlık Regülasyonuna Etkisi

Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis

Contact Info

Product

Resources

About